Tivic Health Systems

Tivic Health Systems ROCE

The Return on Capital Employed (ROCE) of Tivic Health Systems (TIVC) as of Nov 1, 2026 is -47.02 %. In the previous year, Return on Capital Employed (ROCE) was -223.31 % — a change of -78.94% (higher).

ROCE

-47.02 %

YoY

-78.94%

Last updated:

In 2025, Tivic Health Systems's return on capital employed (ROCE) was -47.02 %, a -78.94% increase from the -223.31 % ROCE in the previous year.

The Tivic Health Systems ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
-153.65 USD
Jan 1, 2020
272.22 USD
Jan 1, 2021
-42.44 USD
Jan 1, 2022
-278.18 USD
Jan 1, 2023
-230.31 USD
Jan 1, 2024
-223.31 USD
Jan 1, 2025
-47.02 USD
The Tivic Health Systems ROCE history
YEARROCEYoY
-47.02 %-78.94%
-223.31 %-3.04%
-230.31 %-17.21%
-278.18 %+555.54%
-42.44 %-115.59%
272.22 %-277.17%
-153.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tivic Health Systems Stock analysis

What does Tivic Health Systems do? Tivic Health Systems Inc is a commercial-stage health tech company advancing bioelectronic medicine with patented technology that stimulates trigeminal, sympathetic, and vagus nerve structures. Its first commercial product, ClearUP, is an FDA-approved handheld bioelectronic sinus device clinically proven and doctor-recommended for treating inflammatory chronic conditions. ClearUP is sold directly to consumers in the U.S. through online retailers and commercial distributors, with reseller channels expanding its market reach. The company focuses on expanding its intellectual property portfolio and research programs related to vagus nerve stimulation for broader therapeutic applications. ClearUP serves consumers seeking drug-free therapeutic solutions for sinus conditions, targeting individuals with inflammatory chronic health issues who prefer non-invasive treatments. Healthcare providers recommend ClearUP as a safe, low-risk alternative to medication, appealing to patients looking for high safety profiles in treatment options. The company's revenue streams derive from direct consumer sales and reseller partnerships, leveraging its FDA approval and clinical validation to drive market adoption. Tivic Health Systems develops its products around non-invasive nerve stimulation technology, with ClearUP being the primary revenue-generating product. The company's strategy centers on expanding its IP portfolio to support future product development in bioelectronic medicine, particularly in vagus nerve stimulation applications. By focusing on clinical validation and doctor recommendations, Tivic Health aims to position itself as a leader in drug-free therapeutic solutions for chronic inflammatory conditions. Tivic Health Systems is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Tivic Health Systems's Return on Capital Employed (ROCE)

Tivic Health Systems's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Tivic Health Systems's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Tivic Health Systems's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Tivic Health Systems’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Tivic Health Systems stock

Return on Capital Employed (ROCE) of Tivic Health Systems is -47.02 % in 2025.

Return on Capital Employed (ROCE) of Tivic Health Systems changed from -223.31 % to -47.02 %, representing a -78.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Tivic Health Systems since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Tivic Health Systems with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Tivic Health Systems

All Key Metrics — Tivic Health Systems